August 19, 2025 - InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced the 2025 interim results as of 30 June 2025.
Significant Revenue Growth from Orelabrutinib
Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million[1] for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in marginal zone lymphoma, as well as strong commercial execution. Loss for the period decreased by 86.7% to RMB35.6 million for the six months ended 30 June 2025, attributed to revenue growth and improved cost efficiency.
Research and development expenses increased by 6.9% YoY to RMB449.7 million for the six months ended 30 June 2025 primarily due to increased investment in advanced technology platforms and a greater number of Phase III clinical trials.
Cash and related accounts balances[2] stood at approximately RMB7.7 billion as of 30 June 2025. This robust cash position provides flexibility for the Company to expedite clinical development and invest in a competitive pipeline, including ADC programs.
Accelerating Innovation, Commercialization and Globalization
In the first half of 2025, InnoCare made substantial progress in advancing its pipeline with multiple key milestones achieved: Orelabrutinib received approval for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), tafasitamab in combination with lenalidomide was approved for adult patients with relapsed or refractory DLBCL (R/R DLBCL), BCL-2 inhibitor Mesutoclax (ICP-248) entered two registrational clinical studies, the NDA for TRK inhibitor Zurletrectinib (ICP-723) was accepted and granted priority review, and the Company’s proprietary antibody-drug conjugate (ADC) platform reached a major milestone with IND approval.
Building on this R&D momentum, InnoCare further expanded its global footprint through strategic collaborations. In January, InnoCare partnered with Prolium to explore global potential for a CD3×CD20 bispecific antibody. InnoCare remains committed to advancing global partnerships that will enhance innovation, maximize the value of its pipeline, and support long-term growth.
Orelabrutinib drove significant revenue growth through strong commercial execution and broader market penetration. This momentum demonstrates the Company’s key abilities to translate scientific innovations into sustained business performance.
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “Over the past decade, we have built a fully-integrated platform encompassing original innovation, clinical development, commercialization, manufacturing, and BD, achieving a series of great milestones. As we embark on the next decade, we will accelerate our company's rapid development of Stage 2.0, driving innovation, commercialization, and globalization. Over the next three to five years, we will launch multiple drugs into the market, significantly increasing commercial revenue. We will bring three to four products to the global market. We will also continue to deepen our innovation efforts and develop five to ten differentiated molecules. With our innovative and entrepreneurial spirit, the company is set to reach new heights.”
Building A Leading Franchise in Hemato-Oncology
In the first half of 2025, InnoCare took major steps toward establishing a leadership position in hematology-oncology, driven by three cornerstone therapies - orelabrutinib, tafasitamab, and mesutoclax. With orelabrutinib’s approval in first-line CLL/SLL and tafasitamab’s approval in combination with lenalidomide for adult patients with R/R DLBCL, InnoCare’s commercial hematology portfolio has significantly expanded.
InnoCare’s novel BCL2 inhibitor, mesutoclax, further strengthens this franchise with two registrational trials now underway: a fixed-duration combination regimen with orelabrutinib in 1L CLL/SLL and a ...
(All Rights Reserved)